Related Experiment Videos
Growth factor receptors as molecular targets for cancer diagnosis and therapy
1Department of Radiology, Duke University Medical Center, Durham, NC 27710, USA.
Abstract:
Growth factor receptors are of great interest as molecular targets for the diagnosis and treatment of cancer. Growth factor receptors are frequently over expressed on malignant cell populations since many cellular oncogenes encode either growth factors or their receptors. The wild-type epidermal growth factor receptor has a molecular weight of 170 kD and is over expressed on gliomas, bladder tumors, squamous cells carcinomas and breast carcinomas. Another growth factor oncogene, c-erbB-2, encodes a 185-kD glycoprotein found on the surface of gliomas, breast and ovarian cancers as well as other carcinomas of epithelial origin. In addition to causing over expression, oncogenic transformation also can result in genomic re-arrangements. An important example from the perspective of targeting is EGFRvIII, a deletion mutant which lacks amino acids 6-273 in the extracellular domain of the epidermal growth factor receptor. The EGFRvIII molecule (145 kD) may be of great value for targeting because it appears to be tumor-specific. Antibodies have been developed with specific reactivity with these growth factor receptors. Since these antibodies are internalized into the cell after receptor binding, it is necessary to use radiolabeling methods which residualize the radioactivity in the tumor cell after intracellular catabolism. To investigate this problem, we have evaluated the effect of radioiodination method on the in vitro and in vivo properties of an anti-EGFRvIII antibody. Methods studied were Iodogen, tyramine-cellobiose, and N-succinimidyl 5-iodo-3-pyridine-carboxylate with the last offering optimal localization in a human xenograft model.
Insights
This study evaluated radioiodination methods for an anti-EGFRvIII antibody, crucial for cancer targeting. N-succinimidyl 5-iodo-3-pyridine-carboxylate demonstrated optimal tumor localization in vivo.
Area of Science:
- Oncology
- Immunology
- Radiochemistry
Background:
- Growth factor receptors, like the epidermal growth factor receptor (EGFR), are frequently overexpressed in various cancers, making them key molecular targets for diagnosis and treatment.
- Oncogenic transformation can lead to receptor overexpression and genomic rearrangements, such as the EGFRvIII deletion mutant, which is tumor-specific and a promising target.
- Antibodies targeting these receptors are internalized, necessitating radiolabeling methods that ensure radioactivity retention within tumor cells post-catabolism.
Purpose of the Study:
- To evaluate the impact of different radioiodination methods on the in vitro and in vivo characteristics of an anti-EGFRvIII antibody.
- To identify an optimal radiolabeling technique for enhancing the efficacy of antibody-based cancer therapies targeting EGFRvIII.
Main Methods:
- Comparison of three radioiodination methods: Iodogen, tyramine-cellobiose, and N-succinimidyl 5-iodo-3-pyridine-carboxylate.
- In vitro and in vivo assessment of the resulting radiolabeled anti-EGFRvIII antibody properties.
- Evaluation of antibody localization in a human xenograft cancer model.
Main Results:
- The study compared the efficacy of different radioiodination techniques for an anti-EGFRvIII antibody.
- N-succinimidyl 5-iodo-3-pyridine-carboxylate yielded superior tumor localization compared to Iodogen and tyramine-cellobiose in a human xenograft model.
- This suggests that the choice of radioiodination method significantly impacts the in vivo performance of targeted radiopharmaceuticals.
Conclusions:
- The selection of an appropriate radioiodination method is critical for the development of effective antibody-based cancer therapeutics targeting EGFRvIII.
- N-succinimidyl 5-iodo-3-pyridine-carboxylate is a promising method for radiolabeling anti-EGFRvIII antibodies, offering optimal tumor targeting capabilities.
- Further research into optimized radiolabeling strategies can improve the diagnostic and therapeutic potential of targeted antibodies in oncology.